Thomas Maly, Renaat Coopman, Hugo De Bruyn, Luc Van Doorne
{"title":"Predictive value of Periotest® assessment for failure of Mini Dental Implants supporting maxillary overdentures: a pilot study.","authors":"Thomas Maly, Renaat Coopman, Hugo De Bruyn, Luc Van Doorne","doi":"10.1016/j.jormas.2025.102502","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This prospective cohort study assesses the long-term (5 years) clinical outcome of mini dental implants (MDIs) supporting maxillary overdentures with Periotest® and explores the applicability of Periotest® values (PTV) to predict implant failure.</p><p><strong>Materials and methods: </strong>Included patients were edentulous in the maxilla, dissatisfied with their conventional dentures, and reluctant to undergo augmentation procedures. Per patient, 5 to 8 MDIs (ILZ, Southern Implants Inc., Irene, South Africa) were placed flaplessly. Provisional loading occurred after one week, functional loading after 4-6 months. Periodical assessment up to 5 years after placement was performed with Periotest® (Gulden Medizintechnik, Bensheim an der Bergstraβe, Germany). Statistical analysis compared subgroups nonparametrically, while Pearson correlation analyzed covariance of continuous variables. Linear regression analysis identified predictors for MDI failure. Significance level was set at p < 0.05.</p><p><strong>Results: </strong>Placement of 204 MDIs in 31 patients resulted in a 5 years cumulative failure rate of 23.2%. Successful implants yielded a PTV of 5.87 (SD 5.717) at baseline and 5.37 (SD 6.294) at 5 years respectively (p = 0.336). Failed implants demonstrated elevated last Periotest® measurement 3 months (21.55; SD 8.694; p = 0.007) and 12 months (18.86; SD 10.612; p = 0.007) before failure. A regression analysis with survival time as the dependent factor, identified the last available PTV as a significant predictor of implant failure (p < 0.001; R²=0.451).</p><p><strong>Conclusion: </strong>MDIs are a viable treatment option for supporting maxillary overdentures in last-resort cases with severe atrophy. Periotest® measurements aid monitoring long-term stability in MDIs and attribute to prediction of implant failure.</p>","PeriodicalId":56038,"journal":{"name":"Journal of Stomatology Oral and Maxillofacial Surgery","volume":" ","pages":"102502"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Stomatology Oral and Maxillofacial Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jormas.2025.102502","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Dentistry","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This prospective cohort study assesses the long-term (5 years) clinical outcome of mini dental implants (MDIs) supporting maxillary overdentures with Periotest® and explores the applicability of Periotest® values (PTV) to predict implant failure.
Materials and methods: Included patients were edentulous in the maxilla, dissatisfied with their conventional dentures, and reluctant to undergo augmentation procedures. Per patient, 5 to 8 MDIs (ILZ, Southern Implants Inc., Irene, South Africa) were placed flaplessly. Provisional loading occurred after one week, functional loading after 4-6 months. Periodical assessment up to 5 years after placement was performed with Periotest® (Gulden Medizintechnik, Bensheim an der Bergstraβe, Germany). Statistical analysis compared subgroups nonparametrically, while Pearson correlation analyzed covariance of continuous variables. Linear regression analysis identified predictors for MDI failure. Significance level was set at p < 0.05.
Results: Placement of 204 MDIs in 31 patients resulted in a 5 years cumulative failure rate of 23.2%. Successful implants yielded a PTV of 5.87 (SD 5.717) at baseline and 5.37 (SD 6.294) at 5 years respectively (p = 0.336). Failed implants demonstrated elevated last Periotest® measurement 3 months (21.55; SD 8.694; p = 0.007) and 12 months (18.86; SD 10.612; p = 0.007) before failure. A regression analysis with survival time as the dependent factor, identified the last available PTV as a significant predictor of implant failure (p < 0.001; R²=0.451).
Conclusion: MDIs are a viable treatment option for supporting maxillary overdentures in last-resort cases with severe atrophy. Periotest® measurements aid monitoring long-term stability in MDIs and attribute to prediction of implant failure.
期刊介绍:
J Stomatol Oral Maxillofac Surg publishes research papers and techniques - (guest) editorials, original articles, reviews, technical notes, case reports, images, letters to the editor, guidelines - dedicated to enhancing surgical expertise in all fields relevant to oral and maxillofacial surgery: from plastic and reconstructive surgery of the face, oral surgery and medicine, … to dentofacial and maxillofacial orthopedics.
Original articles include clinical or laboratory investigations and clinical or equipment reports. Reviews include narrative reviews, systematic reviews and meta-analyses.
All manuscripts submitted to the journal are subjected to peer review by international experts, and must:
Be written in excellent English, clear and easy to understand, precise and concise;
Bring new, interesting, valid information - and improve clinical care or guide future research;
Be solely the work of the author(s) stated;
Not have been previously published elsewhere and not be under consideration by another journal;
Be in accordance with the journal''s Guide for Authors'' instructions: manuscripts that fail to comply with these rules may be returned to the authors without being reviewed.
Under no circumstances does the journal guarantee publication before the editorial board makes its final decision.
The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey Platforms.